Working… Menu
Trial record 1 of 1 for:    NCT04310592
Previous Study | Return to List | Next Study

Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04310592
Recruitment Status : Recruiting
First Posted : March 17, 2020
Last Update Posted : March 2, 2021
Information provided by (Responsible Party):
Celularity Incorporated

Brief Summary:
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.

Condition or disease Intervention/treatment Phase
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms by Histologic Type Neoplasms Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Alkylating Agents Antimetabolites, Antineoplastic Antiviral Agents Analgesics, Non-narcotic Anti-infective Agents Analgesics Peripheral Nervous System Agents Hematologic Diseases Hematologic Neoplasms Leukemia in Remission Biological: CYNK-001 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Experimental: Cyclophosphamide + Fludarabine + CYNK-001. On Days 0, 7, and 14, CYNK-001 at 3 varying dose levels.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Primary or Secondary AML in Morphologic Complete Remission With Minimal Residual Disease
Actual Study Start Date : March 12, 2020
Estimated Primary Completion Date : January 3, 2022
Estimated Study Completion Date : January 3, 2022

Arm Intervention/treatment
Experimental: Dose escalation/MTD or MPD determination
Cyclophosphamide + Fludarabine prior to CYNK-001 on Days 0, 7, and 14; CYNK-001 at 3 varying dose levels.
Biological: CYNK-001
CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.

Primary Outcome Measures :
  1. Number of Participants who experience a Dose-limiting Toxicity (DLT) [ Time Frame: Day +28 ]
    The number of participants who experience a DLT will be measured.

  2. Determine the Maximum Tolerated Dose (MTD) or Maximum Planned Dose (MPD) of CYNK-001 [ Time Frame: up to 28 days ]
    The maximum dose safely administered for the treatment of patients with AML.

  3. Frequency and Severity of Adverse Events (AEs) [ Time Frame: up to 12 months ]
    Frequency and severity of Adverse Events will be evaluated.

Secondary Outcome Measures :
  1. Number of Participants who experience Minimal Residual Disease (MRD) Response [ Time Frame: up to 12 months ]
    The number of participants who convert from MRD positive to MRD negative.

  2. Time to MRD Response [ Time Frame: up to 12 months ]
    The time it takes to convert from MRD positive to MRD negative.

  3. Duration of MRD Response [ Time Frame: up to 12 months ]
    The measure of how long participants remain MRD negative.

  4. Progression-free Survival (PFS) [ Time Frame: up to 12 months ]
    Date of first CYNK-001 infusion to date of disease progression.

  5. Time to Progression (TTP) [ Time Frame: up to 12 months ]
    Date of first CYNK-001 infusion to date of disease progression.

  6. Duration of Morphologic Complete Remission (CR) [ Time Frame: up to 12 months ]
    Duration from first Morphologic CR observation to time of disease progression.

  7. Overall Survival (OS) [ Time Frame: up to 12 months ]
    Date of first CYNK-001 infusion to date of death.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Treatment Eligibility Screening Patient Inclusion Criteria

Patients must satisfy the following criteria to be enrolled in the study:

  • Patient has eligible disease status: Primary or Secondary acute myeloid leukemia (AML) Patients in first of second Morphological Complete Remission (CR), Morphological Complete Remission with incomplete hematologic recovery (CRi), or Morphologic Leukemia-free State (MLFS) as defined by the European LeukemiaNet (ELN) recommendations for AML Response Criteria (Dohner, 2017).
  • Patient with prior central nervous system involvement by malignancy are eligible provided that it has been treated and cerebral spinal fluid is clear for at least 2 weeks prior to start of Lymphodepletion Regimen.
  • Patient is minimal residual disease (MRD) positive, as assessed on bone marrow aspirate (BMA) by Multiparameter Flow Cytometry (MFC) at time of Treatment Eligibility assessment.

    o For the purposes of this study, MRD positivity is defined as greater than or equal to 0.1% blasts detected by MFC on BMA by the Sponsor-selected Central MRD analysis laboratory, where assay sensitivity allows for a Lower Limit of Detection (LOD) of 1 x 10-4 (0.01%) or lower.

  • Patient is ≥ 18 and ≤ 80 years of age at the time of signing the Study informed consent form (ICF).
  • Patient understands and voluntarily signs the Study ICF prior to any study-related assessments/procedures are conducted.
  • Patient is willing and able to adhere to the study schedule and other protocol requirements.
  • Performance status of Eastern Cooperative Oncology Group (ECOG) ≤ 2.
  • Ability to be off immunosuppressive drugs for at least 3 days prior to the CYNK-001 infusion. Steroids at the equivalent of no more than 7.5 mg prednisone per day are permissible.
  • Female of childbearing potential (FCBP)* must not be pregnant and agree to not becoming pregnant for at least 28 days following the CYNK-001. FCBP must agree to use an adequate method of contraception during the treatment period.

    • FCBP is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
  • Male Patients must agree to use a condom during sexual contact for at least 28 days following the last infusion of CYNK-001, even if he has undergone a successful vasectomy.

Treatment Eligibility Screening Patient Exclusion Criteria

The presence of any of the following will exclude the Patient from enrollment:

  • Patient has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the Patient from participating in the study.
  • Patient has any condition including the presence of laboratory abnormalities which places the Patient at unacceptable risk if he or she were to participate in the study.
  • Patient has any condition that confounds the ability to interpret data from the study.
  • Patient has bi-phenotypic acute leukemia.
  • Patient has acute promyelocytic leukemia (APL).
  • Patient has inadequate organ function as defined below at time of Treatment Eligibility Period:

    1. Patient has aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase ≥ 2.5 x the upper limit of normal (ULN).
    2. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 as calculated using the Modification of Diet in Renal Disease Study equation (Levey, 2006) or history of an abnormal eGFR < 60 and a decline of > 15 mL/min/1.73 m2 below normal in the past year.
    3. Patient has a bilirubin level > 2 mg/dL (unless Patient has known Gilbert's disease).
  • Patient has had prior treatment with biologic antineoplastic agents less than 7 days before first CYNK-001 infusion and at least 5 half-lives. (Exception will be granted for monoclonal antibodies that are known to have long half-lives, in which case a minimum of 2 weeks from last dose will be required). For agents that have known AEs occurring beyond these specified days after administration, this period must be extended beyond the time during which acute AEs are known to occur. Treating physicians are encouraged to discuss cases with the Medical Monitor.
  • Patient is pregnant or breastfeeding.
  • Patient has new or progressive pulmonary infiltrates or pleural effusion large enough to be detected by chest x-ray or CT scan within 2 weeks of first CYNK-001 infusion.
  • Patient has active autoimmune disease other than controlled connective tissue disorder or those who are not on active therapy.
  • Patient has had a Bone Marrow transplant as part of their anti-AML treatment prior to first CYNK-001 infusion or plans to have transplant within the 28 day period following first CYNK-001 infusion. Exception includes relapsed patients who received prior Bone Marrow transplant as part of their treatment plan at initial diagnosis.
  • Patient has a history of malignancy other than AML or other underlying hematologic conditions such as myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) unless the Patient has been free of disease for greater than 3 years prior to CYNK 001 infusion. Exceptions will include the following malignancies:

    1. Basal cell carcinoma of the skin
    2. Squamous cell carcinoma of the skin
    3. Carcinoma in situ of the cervix
    4. Carcinoma in situ of the breast
    5. Incidental biological finding of prostate cancer (TNM stage of T1a or T1b)
  • Patient has a history of severe asthma and is presently on chronic medications or has a history of other symptomatic pulmonary disease.
  • Patient has uncontrolled graft versus host disease (GVHD) or GVHD requiring treatment with corticosteroids.
  • Patient has an untreated chronic infection or has received treatment of any infection with systemic antibiotics within 2 weeks prior to first CYNK-001 infusion. Prophylactic antibiotic, antiviral, and antifungal medication are permissible.
  • Patient has any other organ dysfunction (CTCAE Version 5.0 Grade 3 or greater) that will interfere with the administration of the therapy according to this protocol.
  • Patient has a resting left ventricular ejection fraction (LVEF) of < 45% obtained by echocardiography or multi-gated acquisition scan (MUGA).
  • Patient was treated with an investigational product within 28 days of first CYNK-001 infusion. Patient must no longer be a participant in the previous interventional study at the time of CYNK-001 infusion. (Patients who are under survival follow-up or observation associated with a study are permitted, and if treatment information is collected for this period, "Investigational Study" must be used to capture the study treatment.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04310592

Layout table for location contacts
Contact: Erica Rave, MS 9088454338
Contact: Solveig Ericson, MD, PhD 9088454182

Layout table for location information
United States, Colorado
Colorado Blood Cancer Institute Recruiting
Denver, Colorado, United States, 80218
Principal Investigator: Michael Maris, MD         
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Hongtao Liu, MD, PhD         
Principal Investigator: Hongtao Liu, MD, PhD         
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: James McCloskey, MD         
Principal Investigator: James McCloskey, MD         
United States, New York
Roswell Park Comprehensive Cancer Center Recruiting
Buffalo, New York, United States, 14203
Contact: Eunice Wang, MD         
Principal Investigator: Eunice Wang, MD         
Columbia University and New York Presbyterian Hospital Recruiting
New York, New York, United States, 10032
Contact: Joseph Jurcic, MD, PhD         
Principal Investigator: Joseph Jurcic, MD, PhD         
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Aaron Goldberg, MD, PhD         
Principal Investigator: Aaron Goldberg, MD, PhD         
United States, Tennessee
Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
Contact: MD         
Principal Investigator: William Donnellan, MD         
United States, Washington
Swedish Health Services Not yet recruiting
Seattle, Washington, United States, 98122
Contact: Daniel Egan, MD         
Principal Investigator: Daniel Egan, MD         
Sponsors and Collaborators
Celularity Incorporated
Layout table for investigator information
Study Director: Solveig Ericson, MD, PhD Celularity, Inc.
Layout table for additonal information
Responsible Party: Celularity Incorporated Identifier: NCT04310592    
Other Study ID Numbers: CYNK-001-AML-001
First Posted: March 17, 2020    Key Record Dates
Last Update Posted: March 2, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Celularity Incorporated:
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
allogeneic stem cell transplant
cell therapy
minimal residual disease
newly diagnosed AML
newly diagnosed acute myeloid leukemia
NK cells
natural killer cells
fludarabine phosphate
antineoplastic agents, alkylating
molecular mechanisms of pharmacological action
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Hematologic Neoplasms
Neoplasms by Histologic Type
Hematologic Diseases
Neoplasms by Site